Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Commerce Lowers Cambrex to 'Market Perform'

Commerce Capital downgraded Cambrex (CBM) to market perform.

Analyst Christopher Crooks says he downgraded after the provider of services to the life sciences industry cut the 2003 guidance, and said it decided to enter into a settlement and indemnity agreement with Mylan Labs for current and future claims.

He notes Cambrex now forecasts 2003 earnings per share of $1.05-$1.25, including a special charge for the settlement; excluding the charge, the company sees earnings per share of $1.37-$1.57. As such, he cut his $2.10 2003 earnings per share from operations estimate to $1.40. He says his downgrade will stand until he gets a better sense of fundamental improvement. Also, Crooks notes Cambrex reduced the 2003 revenue guidance for both its biosciences and human health segments.

blog comments powered by Disqus